82 related articles for article (PubMed ID: 23292115)
1. Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.
Jiang F; Yeo CW; Lee SS; Oh MK; Ghim JL; Shon JH; Kim HS; Kim EY; Kim DH; Shin JG
Pharmacogenet Genomics; 2013 Mar; 23(3):175-9. PubMed ID: 23292115
[TBL] [Abstract][Full Text] [Related]
2. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Dispos; 2010 Sep; 38(9):1456-63. PubMed ID: 20530222
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
5. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Pharmacokinet; 2011 Jun; 26(3):236-41. PubMed ID: 21273733
[TBL] [Abstract][Full Text] [Related]
7. Food increases the bioavailability of tolterodine but not effective exposure.
Olsson B; Brynne N; Johansson C; Arnberg H
J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
9. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
10. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
Postlind H; DanielsonA ; Lindgren A; Andersson SH
Drug Metab Dispos; 1998 Apr; 26(4):289-93. PubMed ID: 9531513
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
Brynne N; Svanström C; Aberg-Wistedt A; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
[TBL] [Abstract][Full Text] [Related]
13. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.
Brynne N; Stahl MM; Hallén B; Edlund PO; Palmér L; Höglund P; Gabrielsson J
Int J Clin Pharmacol Ther; 1997 Jul; 35(7):287-95. PubMed ID: 9247842
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
Påhlman I; Kankaanranta S; Palmér L
Arzneimittelforschung; 2001 Feb; 51(2):134-44. PubMed ID: 11258043
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine.
Byeon JY; Lee CM; Lee YJ; Kim YH; Kim SH; Jung EH; Chae WK; Lee YJ; Jang CG; Lee SY
Arch Pharm Res; 2019 Feb; 42(2):182-190. PubMed ID: 30542809
[TBL] [Abstract][Full Text] [Related]
18. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
19. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine extended-release for overactive bladder.
Chung DE; Te AE
Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
